Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed objectives and criteria for a clinical trial involving pembrolizumab in metastatic non-squamous non-small cell lung cancer, while adding new identifiers and collaborators.SummaryDifference49%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check67 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.